Trends in Skeletal Muscle Relaxant Prescribing Examined
Office visits with prescribed SMR nearly doubled; tripling in visits for continued SMR drug therapy.
Miscellaneous Musculoskeletal Disorders
Casimersen NDA Submitted for Duchenne Muscular Dystrophy
Sarepta Therapeutics has completed the submission of the casimersen (SRP-4045) NDA for the treatment of Duchenne muscular dystrophy in patients who have genetic mutations that are amenable to skipping exon 45 of the Duchenne gene.
Contraceptives Beneficial for Premature Ovarian Insufficiency
Combined oral contraceptives linked to improvement in bone mass, similar to that with high-dose HT.
Small Increase Seen in Risk for Subdeltoid Bursitis With Flu Shot
Attributable risk was 7.78 additional cases of subdeltoid bursitis per million persons vaccinated.
Implantable Neurostimulation Device Cleared for Chronic Low Back Pain
The FDA has approved ReActiv8® (Mainstay Medical), an implantable neurostimulation system, for the treatment of intractable chronic low back
Crysvita Approved for Treatment of Tumor-Induced Osteomalacia
The FDA as approved Crysvita® (burosumab-twza; Ultragenyx) for the treatment of fibroblast growth factor 23 (FGF23)-related hypophosphatemia in tumor-induced osteomalacia associated with phosphaturic mesenchymal tumors that cannot be curatively resected or localized in patients aged ≥2 years.
Tramadol Linked to Increased Hip Fracture Risk in Adults Aged ≥50
Risk for hip fracture over one year higher for those initiating tramadol compared with codeine, common NSAIDs.
Novel Therapy for Prosthetic Joint Infections Gets Orphan Drug Status
The FDA has granted Orphan Drug designation to TNP-2092 (TenNor Therapeutics) powder for intravenous IV injection for the treatment of prosthetic joint infections.
Four Weeks of Active TENS Beneficial for Fibromyalgia
Greater decline seen in movement-evoked pain, fatigue; more improvement found on global impression of change
FDA Approves Vyondys 53 for Duchenne Muscular Dystrophy
The FDA has granted accelerated approval to Vyondys 53 (golodirsen; Sarepta Therapeutics) injection for the treatment of Duchenne muscular dystrophy.
